Prudent utilization of the presently available treatment modalities for type 2 diabetes

Endocrinologist

Volumn 8, Issue 5, 1998, Pages 332-341

  Bell, David S H ^a,b  

^a University of Alabama at Birmingham   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ALGORITHM; DRUG MIXTURE; HUMAN; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TREATMENT PLANNING;

EID: 0031761317     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-199809000-00004     Document Type: Review

References (35)

1. Gerich, JE: Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-45.
2. Bell DSH, Yumuk V: Frequency of severe hypoglycemia in patients with non-insulin dependent diabetes mellitus treated with sulfonylureas or insulin. Endoc Prac 1997; 3: 281-3.
3. Smits P, Thien T: Cardiovascular effects of sulfonylurea derivatives: implications for the treatment of NIDDM? Diabetologia 1995; 38: 16-21.
4. Meinert CL, Knatterud GL, Prout TE, Klimt CR (University Group Diabetes Program): A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes mellitus. II Mortality results. Diabetes 1970; 19(Suppl.): 789-830.
5. Andreotti F, Pasceri V, Hackett DR, Davis GJ, Haider AW, Maseri A: Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Eng J Med 1996; 334: 7-12.
6. Tomai F, Crea F, Gaspardone A, et al: Ischemic pre-conditioning during coronary angioplasty is prevented by glibenclamide a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700-5.
7. Bijlstra P, Lutterman J, Russell FGM, Thien T, Smits P: Interaction of sulfonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 1996; 39: 1083-90.
8. Bijlstrea PJ, Russell FGM, Thien T, Lutterman JA, Smits P: Effects of tolbutamide on vascular ATP sensitive potassium channels in humans: comparison with literature data on glibenclamide and glimeperide. Horm Metab Res 1996; 28: 512-6.
9. Ballagi-Pordany G, Nemeth M, Aranyi Z, et al.: Effect of glimeperide on the electrical activity of isolated rabbit heart muscle. Arzmemittelforschung 1992; 42: 111-3.
10. Draeger KE, Wernicke-Panter K, Lomp HJ, Schuler E, Rosskamp R: Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimeperide (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996; 28: 419-25.
11. Bloomgarden ZT: New therapeutic approaches to non-insulin-dependent diabetes mellitus. Endoc Prac 1997; 3: 307-12.
12. Bell DSH: University Group Diabetes Program - "Deja vu all over again?" Endoc Prac 1998; 4: 64-5.
13. Bailie CJ: Biguanides and NIDDM. Diabetes Care (1992) 15: 752-8.
14. Stumoli M, Nurjhun N, Perriello G. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550-6.
15. Lee A, Bray GA: Metformin decreases food consumption in obese non-insulin-dependent diabetes (NIDDM). Diabetes 1996; 45 (Suppl. 2): 170A.
16. Leslie P, Jung RT, Isles TE, Baty J: Energy expenditure in non-insulin-dependent diabetic subjects on Metformin or sulfonylurea therapy. Clin Sci 1987; 73: 41-5.
17. Bell DSH, Mayo MS: Weight loss in diabetic patients treated with metformin and sulfonylurea combination compared with twice daily mixed insulin regimen. Endoc Prac (in press).
18. Coniff RF, Shapiro JA, Seaton TB: Multicenter placebo-controlled trial comparing acarbose (BAYg5421) with placebo, tolbutamide and tolbutamide plus acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-51.
19. Santeasanio F, Ventura MM, Contadini S: Efficacy and safety of two different doses of acarbose in non-insulin-dependent diabetes treated by diet alone. Diabetes Nutr Metab 1993; 6: 147-54.
20. Salterl AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 661-9.
21. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effect of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203.
22. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, FAJA BW: The Troglitazone Study Group and Randall W. Whitcomb. Cardiac and glycemic benefits of troglitazone treatment in non-insulin-dependent diabetes. Diabetes 1997; 46: 433-9.
23. Bell DSH, Mayo MS: Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus. Endoc Prac 1997; 3: 73-6.
24. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS: Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524-30.
25. Nestler JH, Jakubowicz DJ: Decreases in ovarian cytochrome P450cl7a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617-23.
26. DeFronzo RA, Barzilia W, Simonson DC: Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-301.
27. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Shulman GL: Efficacy and metabolic effects of troglitazone and metformin in NIDDM. Diabetes 1997; 46 (Suppl.1): 34A.
28. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-4.
29. Ghazzi M, Radke-Mitchell L, Venable T: The Troglitazone Study Group Whitcomb R. Diabetes 1997; 46 (Suppl. 1): 44A.
30. Chaisson J L, Josse RG, Hung J A, et al.: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-35.
31. Riddle MC, Karl DM: Systematically combining treatments for type 2 diabetes. Prac Diabetol 1995; 14: 2-5.
32. Riddle MC, Hant J, Bingham P, Garrison C, McDaniel P: Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci 1992; 303: 151-6.
33. Yki-Jarvinen H, Kauppila M, Kujansue E, et al.: Comparison of insulin regimens in patients with, non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 426-33.
34. Bell DSH, Mayo MS: Improved glycemic control on oral hypoglycemic therapy with or without insulin. Endoc Prac 1998; 4: 82-5.
35. Raskin P, Graveline JF: Efficacy of troglitazone in combination with insulin in NIDDM. Diabetes 1997; 46 (Suppl. 1): 44A.